John de Kruif
Chief Tech/Sci/R&D Officer chez MERUS N.V.
Profil
John de Kruif is currently the Chief Technology Officer & Senior Vice President at Merus NV since 2013.
Prior to his current position, he worked as the Director-Antibody Discovery at Crucell NV from 2000 to 2006.
Dr. de Kruif holds a doctorate degree from the University of Utrecht.
Postes actifs de John de Kruif
| Sociétés | Poste | Début |
|---|---|---|
| MERUS N.V. | Chief Tech/Sci/R&D Officer | 01/04/2007 |
Anciens postes connus de John de Kruif
| Sociétés | Poste | Fin |
|---|---|---|
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | 01/10/2006 |
Formation de John de Kruif
| University of Utrecht | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERUS N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
